
HIV type 2 subtype A (isolate BEN) Gag 181-189, CTPYDINQM
Description
About HIV type 2 subtype A (isolate BEN) Gag 181-189, CTPYDINQM
The Human immunodeficiency virus (HIV) type 2 subtype A (isolate BEN) Gag polyprotein (gag) Peptide (IEDB: 7197) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Gag polyprotein (gag) Peptide, H-CTPYDINQM-OH (Uniprot: P18095 aa: 181-189) from JPT is produced under strict quality control and quality management.
HIV type 2 subtype A (isolate BEN) Gag 181-189, CTPYDINQM - Specifications
- Peptide sequence: H-CTPYDINQM-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): AIDS (HIV)
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for HIV type 2 subtype A (isolate BEN) Gag 181-189, CTPYDINQM
References:
Read References with JPT’s Antigen Peptides
HIV type 2 subtype A (isolate BEN) Gag 181-189, CTPYDINQM has been described in:
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results., Nat Med, 2022 (PMID: 35970920)
Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus., J Immunol, 1998 (PMID: 9637523)
Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF., Front Immunol, 2020 (PMID: 32582212)
Documentation
Documentation for HIV type 2 subtype A (isolate BEN) Gag 181-189, CTPYDINQM
Properties
Properties of HIV type 2 subtype A (isolate BEN) Gag 181-189, CTPYDINQM
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | AIDS (HIV) |
Layout: | Freeze-dried in glass vial |
Organism: | Human immunodeficiency virus (HIV) |
Protein Name: | Gag polyprotein (gag) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to HIV type 2 subtype A (isolate BEN) Gag 181-189, CTPYDINQM
Information | Values |
---|---|
Sequence: | H-CTPYDINQM-OH |
Specifications: | 9mer peptide as TFA salt |